Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy

Area of Science:

• Cancer immunology
• Molecular oncology
• Biochemistry

Background:

• Programmed cell death-ligand 1 (PD-L1) is a key regulator of immunosuppression in cancer.
• PD-L1 expression is modulated by various posttranslational modifications (PTMs).
• Aberrant PTMs of PD-L1 contribute to immune evasion in cancer patients.

Purpose of the Study:

• To review the regulatory roles of PD-L1 PTMs in cancer.
• To explore the therapeutic potential of targeting PD-L1 PTMs for cancer treatment.

Main Methods:

• Literature review of studies on PD-L1 PTMs.
• Analysis of preclinical data on targeting PD-L1 PTMs.

Main Results:

• Glycosylation, phosphorylation, ubiquitination, sumoylation, and acetylation are critical PTMs affecting PD-L1 stability, translocation, and interactions.
• Targeting PD-L1 PTMs with natural compounds, small molecules, or antibodies demonstrates significant antitumor effects in preclinical models.
• These findings highlight novel signaling pathways regulating PD-L1.

Conclusions:

• Modulating PD-L1 PTMs represents a promising strategy for cancer immunotherapy.
• Targeting PD-L1 PTMs warrants further clinical investigation for cancer treatment.